Gilead Sciences

Q3 FY2026 EarningsQ3 FY26 beat consensus on the top-line with revenue of $8.30B vs. $7.80B expected, driven by 18% YoY growth in HIV sales ($6.25B). GAAP EPS of $1.94 exceeded the $1.78 mean estimate (+9.27%) despite a significant miss on gross margin (81.07% vs. 86.90% expected). Growth in Trodelvy (+42% YoY) and Liver Disease (+13% YoY) offset the continued decline in Veklury sales (-69% YoY), while elevated operating expenses reflected ongoing M&A integration and legal costs.